Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abderrahim Fandi

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The International Journal of Biochemistry & Cell Biology|April 11, 2008
Overcoming kinase resistance in chronic myeloid leukemiaFrancis Lee, Abderrahim Fandi, Maurizio Voi
Clinical Lung Cancer|June 10, 2005
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancerChristian Manegold, Ulrich Gatzemeier, Erika Buchholz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancerPeter M Ellis, Ulf Jungnelius, Jennie Zhang, et al.
Oncology Reports|January 19, 2008
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell linesFabio Timeus, Nicoletta Crescenzio, Abderrahim Fandi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patientsJean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Journal of Cancer Research and Clinical Oncology|September 13, 2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapyGiuseppe Giaccone, Renee B Iacona, Abderrahim Fandi, et al.
European Urology|October 27, 2015
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving DocetaxelGuru Sonpavde, Gregory R Pond, Arnoud J Templeton, et al.
Clinical Breast Cancer|April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST AnalysisJavier Cortes, José Pérez-García, Scott Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancerPrimo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The International Journal of Biochemistry & Cell Biology|April 11, 2008
Overcoming kinase resistance in chronic myeloid leukemiaFrancis Lee, Abderrahim Fandi, Maurizio Voi
Clinical Lung Cancer|June 10, 2005
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancerChristian Manegold, Ulrich Gatzemeier, Erika Buchholz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancerPeter M Ellis, Ulf Jungnelius, Jennie Zhang, et al.
Oncology Reports|January 19, 2008
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell linesFabio Timeus, Nicoletta Crescenzio, Abderrahim Fandi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patientsJean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Journal of Cancer Research and Clinical Oncology|September 13, 2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapyGiuseppe Giaccone, Renee B Iacona, Abderrahim Fandi, et al.
European Urology|October 27, 2015
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving DocetaxelGuru Sonpavde, Gregory R Pond, Arnoud J Templeton, et al.
Clinical Breast Cancer|April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST AnalysisJavier Cortes, José Pérez-García, Scott Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancerPrimo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Pageof 2